Rambøll Denmark A/S was appointed by Novo Nordisk A/S for the design of a new production facility which will deliver the world’s first protein tablet to the global market.
The building is approximately 10.000 m2, including production, packaging, inventory and shipping, as well as the common building and canteen. In this project, time is a crucial factor, as the production should be commissioned as soon as possible to get the product on the market. The project is therefore executed with a optimised “fast track” process, in which both design and construction are executed in parallel staggered phases. This requires extraordinary demands of coordination, quality assurance and a rigorous decision-making process.
To minimize negative weather influences on the execution phase, the whole building was covered in a large construction tent until the shell construction was completed. The building will be handed over in 2017 and will be fully GMP validated by 2018.
The design frame is dictated by the overall master plan of which the building is a part of: all the buildings have the same top level façade, grey smooth finish masonry with no plinths, square white window sections and light coatings of zinc or aluminium.
Ramboll has provided services from conceptual brief to detail design, as well as construction management (EPCM), including architecture, structures, electrical engineering , security, fire, HVAC , cooling system, sprinkler system, pure gases, vacuum system, underground cables and construction management of about 50 subcontractors, as well as supervision and follow-up.